WO2001034131A3 - Combination chemotherapy - Google Patents

Combination chemotherapy Download PDF

Info

Publication number
WO2001034131A3
WO2001034131A3 PCT/US2000/030377 US0030377W WO0134131A3 WO 2001034131 A3 WO2001034131 A3 WO 2001034131A3 US 0030377 W US0030377 W US 0030377W WO 0134131 A3 WO0134131 A3 WO 0134131A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination chemotherapy
combination
chemotherapy
acetyldinaline
carboplatin
Prior art date
Application number
PCT/US2000/030377
Other languages
French (fr)
Other versions
WO2001034131A2 (en
Inventor
Ronald Lynn Merriman
Wayne Daniel Klohs
Original Assignee
Warner Lambert Co
Ronald Lynn Merriman
Wayne Daniel Klohs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Ronald Lynn Merriman, Wayne Daniel Klohs filed Critical Warner Lambert Co
Priority to EP00978360A priority Critical patent/EP1229916A2/en
Priority to CA002386876A priority patent/CA2386876A1/en
Priority to IL14936300A priority patent/IL149363A0/en
Priority to KR1020027005970A priority patent/KR20020060226A/en
Priority to NZ518668A priority patent/NZ518668A/en
Priority to JP2001536131A priority patent/JP2003513912A/en
Priority to AU15832/01A priority patent/AU1583201A/en
Priority to HU0203153A priority patent/HUP0203153A3/en
Publication of WO2001034131A2 publication Critical patent/WO2001034131A2/en
Publication of WO2001034131A3 publication Critical patent/WO2001034131A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Acetyldinaline in combination with paclitaxel and/or carboplatin is synergistic for treating cancer.
PCT/US2000/030377 1999-11-10 2000-11-03 Combination chemotherapy WO2001034131A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP00978360A EP1229916A2 (en) 1999-11-10 2000-11-03 Combination chemotherapy
CA002386876A CA2386876A1 (en) 1999-11-10 2000-11-03 Combination chemotherapy
IL14936300A IL149363A0 (en) 1999-11-10 2000-11-03 Combination chemotherapy
KR1020027005970A KR20020060226A (en) 1999-11-10 2000-11-03 Combination Chemotherapy
NZ518668A NZ518668A (en) 1999-11-10 2000-11-03 Combination chemotherapy comprising acetyldinaline and paclitaxal and/or carboplatin
JP2001536131A JP2003513912A (en) 1999-11-10 2000-11-03 Combination chemotherapy
AU15832/01A AU1583201A (en) 1999-11-10 2000-11-03 Combination chemotherapy
HU0203153A HUP0203153A3 (en) 1999-11-10 2000-11-03 Combination chemotherapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16488999P 1999-11-10 1999-11-10
US60/164,889 1999-11-10
US22256100P 2000-08-03 2000-08-03
US60/222,561 2000-08-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10148063 A-371-Of-International 2002-05-24
US10/286,498 Division US20030134893A1 (en) 1999-11-10 2003-02-20 Combination chemotherapy

Publications (2)

Publication Number Publication Date
WO2001034131A2 WO2001034131A2 (en) 2001-05-17
WO2001034131A3 true WO2001034131A3 (en) 2002-05-10

Family

ID=26860956

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030377 WO2001034131A2 (en) 1999-11-10 2000-11-03 Combination chemotherapy

Country Status (17)

Country Link
EP (1) EP1229916A2 (en)
JP (1) JP2003513912A (en)
KR (1) KR20020060226A (en)
CN (1) CN1387438A (en)
AR (1) AR026400A1 (en)
AU (1) AU1583201A (en)
CA (1) CA2386876A1 (en)
GT (1) GT200000194A (en)
HU (1) HUP0203153A3 (en)
IL (1) IL149363A0 (en)
NZ (1) NZ518668A (en)
PA (1) PA8506201A1 (en)
PE (1) PE20011028A1 (en)
PL (1) PL355170A1 (en)
SV (1) SV2001000212A (en)
UY (1) UY26431A1 (en)
WO (1) WO2001034131A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022216A3 (en) * 2001-07-02 2003-05-14 Warner-Lambert Company Compound chemotherapy
PE20050206A1 (en) * 2003-05-26 2005-03-26 Schering Ag PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE
DK1696898T3 (en) 2003-12-02 2016-02-22 Univ Ohio State Res Found ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
WO2006008639A1 (en) * 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
EP2415382B1 (en) 2010-08-06 2012-08-29 Electrolux Home Products Corporation N.V. Table top dishwasher
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137918A (en) * 1986-04-22 1992-08-11 Goedecke Aktiengesellschaft N-(2'-aminophenyl)-benzamide derivatives process for the preparation thereof and pharmaceutical compositions containing them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137918A (en) * 1986-04-22 1992-08-11 Goedecke Aktiengesellschaft N-(2'-aminophenyl)-benzamide derivatives process for the preparation thereof and pharmaceutical compositions containing them

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BELANI CHANDRA P ET AL: "Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, no. 2, February 1999 (1999-02-01), pages 676 - 684, XP001015617, ISSN: 0732-183X *
HOWARD C T ET AL: "IN VIVO ANTITUMOR ACTIVITY OF CI-994 (N-ACETYL-DINALINE, GOE 5549) ALONE AND IN COMBINATION WITH GEMCITABINE AGAINST LC12 SQUAMOUS CELL LUNG CARCINOMA", PROCEEDINGS OF THE 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. PHILADELPHIA, PA, APRIL 10 - 14, 1999, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA: AACR, US, vol. 40, March 1999 (1999-03-01), pages 590, XP000857907 *
SCHAIDER H ET AL: "COMBINATION TREATMENT BASED ON METABOLIC EFFECTS OF DINALINE", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 121, no. 4, 1995, pages 203 - 210, XP000865863, ISSN: 0171-5216 *

Also Published As

Publication number Publication date
WO2001034131A2 (en) 2001-05-17
CA2386876A1 (en) 2001-05-17
HUP0203153A2 (en) 2003-01-28
JP2003513912A (en) 2003-04-15
AR026400A1 (en) 2003-02-12
PL355170A1 (en) 2004-04-05
PE20011028A1 (en) 2001-10-12
HUP0203153A3 (en) 2005-01-28
AU1583201A (en) 2001-06-06
IL149363A0 (en) 2002-11-10
PA8506201A1 (en) 2002-12-11
KR20020060226A (en) 2002-07-16
CN1387438A (en) 2002-12-25
GT200000194A (en) 2002-05-03
EP1229916A2 (en) 2002-08-14
UY26431A1 (en) 2000-12-29
SV2001000212A (en) 2001-10-25
NZ518668A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
AU4768301A (en) Synergistic methods and compositions for treating cancer
HK1022301A1 (en) Conjugates of cisdocosahexaenoic acid and paclitaxel
MXPA02001508A (en) Arylmethylcarbonylaminothiazole derivatives and their use as antitumor agents.
WO2002066019A3 (en) Cancer treatment
NZ241627A (en) Quinazoline derivatives and anti-tumour compositions
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
WO2004034990A3 (en) Methods and compositions for use in treating cancer
WO2004012662A3 (en) Improved treatment of cancer with glutamine
ZA979095B (en) HIV and cancer treatments.
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
WO2001034131A3 (en) Combination chemotherapy
AU2158601A (en) Antiviral agent for use in treatment of cancer
AU2002346644A1 (en) Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2002102306A3 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
ZA200202822B (en) Oncolytic combinations for the treatment of cancer.
AU5576601A (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
EP1273296A3 (en) Combination chemotherapy
IL143012A0 (en) Pharmaceutical composition comprising an anti-cancer agent and at least one peptide
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2002024179A3 (en) Method for reducing toxicity of combined chemotherapies
AU2001261360A1 (en) R-eliprodil for treating glaucoma
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
AU2003280341A1 (en) Synergistic combinations of dietary fiber and n-saids for the treatment of cancer
WO2002024178A3 (en) Method for reducing toxicity of combined chemotherapies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2386876

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 149363

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 518668

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000978360

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020027005970

Country of ref document: KR

Ref document number: 008154708

Country of ref document: CN

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 536131

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 15832/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10148063

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020027005970

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000978360

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 518668

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 518668

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000978360

Country of ref document: EP